

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments	
43251	17/WM/0308	226910	Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (C)	Number Agreed	2	2	Not Available / Not Agreed		15/01/2019	0		Recruitment Finished		
43252	17/LO/0925	223376	A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) ? SELECT ? PsA 2	Number Agreed	1	1	Date Agreed	29/04/2019	0	30/01/2019	0		Recruitment Finished	
43253	16/LO/0877	202257	A PHASE 3, MULTICENTER, MULTINATIONAL RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB* (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WHO COMPLETED FIRST-LINE CHEMOTHERAPY FOR UNRESECTABLE, LOCALLY ADVANC	Number Agreed	2	2	Date Agreed	28/02/2019	1	21/02/2019	1		Recruitment Finished	
43254	17/EE/0497	238458	A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 100 mg b.i.d. in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EMFADINE)	Number Agreed	4	4	Date Agreed	20/12/2019	0	25/02/2019	0		Withdrawn By Sponsor	
43255	15/SC/0303	167788	A prospective non-interventional post-authorization safety study (PASS), designed as a disease registry of patients with transfusion dependent IPSS low or intermediate-1-risk myelodysplastic syndromes (MDS) and isolated del(5q)	Number Agreed	1	1	Date Agreed	29/03/2019	0	29/03/2019	0		Recruitment Finished	
43256	14/SC/1350	166544	A non-interventional post authorisation registry of patients treated with pomalidomide for relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstr	Number Agreed	2	2	Date Agreed	31/03/2019	2	01/04/2019	2		Recruitment Finished	
43257	15/LO/1066	149302	Inlyta In Advanced / Metastatic Renal Cell CarcinOma - A Non-Interventional Study of Real World Treatment Outcomes in Patients Receiving 2nd Line Inlyta after 1st Line Sulfent	Number Agreed	8	8	Date Agreed	30/04/2019	6	30/04/2019	6		Recruitment Finished	
43258	16/WM/0250	194366	A prospective, multi-national, multicentre, non-interventional study to evaluate the long term safety of Esmya, in particular the endometrial safety, and the current prescription and management patterns of Esmya in a long term treatment setting	Number Agreed	10	10	Date Agreed	30/04/2019	17	30/04/2019	17		Recruitment Finished	
43259	16/SC/0615	210762	A Phase 4 open-label randomized controlled study (Comparing the effectiveness of adalimumab INTRODUCTION and methotrexate dose escalation in subjects with Psoriatic Arthritis (CONTROL)	Number Agreed	3	3	Date Agreed	02/05/2019	3	02/05/2019	3		Recruitment Finished	
43260	17/WM/0250	228393	Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)	Number Agreed	1	1	Date Agreed	30/06/2019	1	30/06/2019	1		Recruitment Finished	
43261	16/WM/0289	204062	A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myelomapatients - the INSIGHT-MM study	Number Agreed	10	10	Date Agreed	31/07/2019	39	03/07/2019	39		Recruitment Finished	
43262	19/SC/0040	257213	Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis	Number Agreed	2	2	Date Agreed	30/04/2020	0	03/09/2019	0		Withdrawn By Sponsor	
43263	17/SW/0221	232448	A randomized, partially-blinded, active-controlled, multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy	Number Agreed	2	2	Date Agreed	27/06/2019	3	06/08/2019	3		Recruitment Finished	
43264	16/LO/0778	245359	Use Via Early Access to Ixazomib	Number Agreed	12	12	Date Agreed	01/04/2019	8	31/08/2019	14		Recruitment Finished	
43265	18/SC/0241	244567	A phase 2a proof of concept, randomised, double-blind, placebo-controlled study to evaluate the safety/tolerability and efficacy of 4 subcutaneous injections of namlumab (150 mg) given over 10 weeks in subjects with moderate-to-severely active axial	Number Agreed	2	2	Date Agreed	27/09/2019	2	27/09/2019	2		Recruitment Finished	
43266	13/SW/0159	131018	NN304-4016 Diabetes Pregnancy Registry	Number Agreed	25	25	Date Agreed	30/09/2018	25	30/09/2019	25		Recruitment Finished	